Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke

ZHANG Dian; HAN Ruodong; LI Bing; GUO Zhiyi

doi:10.16766/j.cnki.issn.1674-4152.004085

Volume 23 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2025 > 23(7): 1148-1151

ZHANG Dian, HAN Ruodong, LI Bing, GUO Zhiyi. Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke[J]. Chinese Journal of General Practice, 2025, 23(7): 1148-1151. doi: 10.16766/j.cnki.issn.1674-4152.004085

Citation:

ZHANG Dian, HAN Ruodong, LI Bing, GUO Zhiyi. Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke[J]. Chinese Journal of General Practice, 2025, 23(7): 1148-1151. doi: 10.16766/j.cnki.issn.1674-4152.004085

Citation:

PDF( 424 KB)

Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke

doi: 10.16766/j.cnki.issn.1674-4152.004085

ZHANG Dian¹
, HAN Ruodong^{2
,
,}
, LI Bing³
, GUO Zhiyi¹

1.
Department of Pharmacy, Bozhou People's Hospital, Bozhou, Anhui 236800, China

Funds:

2022AH050688

Received Date: 2024-05-04

Abstract

Abstract

Objective To explore the clinical efficacy, neurological function, inflammatory levels, and free radical levels of edaravone dexborneol combined with argatroban in patients with acute ischemic stroke (AIS). Methods A total of 80 patients with AIS admitted to Bozhou People ' s Hospital from January 2022 to December 2023 were selected and divided into the control group (40 cases) and treatment group (40 cases) based on the random number method. The control group was given argatroban and the treatment group was given argatroban combined with edaravone dexborneol. The clinical efficacy, related scale scores, serum inflammatory factors, free radicals and the occurrence of adverse reactions were compared between the two groups. Results After treatment, the total efficacy rate for the treated group was significantly better than the achieved by the control group [95.0% (38/40) vs. 80.0% (32/40), P < 0.05]. After 2 weeks of treatment, the NIHSS score and modified Rankin score in the treatment group were lower than those in the control group, while the Barthel index score was higher than that in the control group (P < 0.05). The levels of hypersensitive C-reactive protein, interleukin-1β, interleukin-6, and tumor necrosis factor-α in the treatment group were lower than those in the control group (P < 0.05). The levels of malondialdehyde and reactive oxygen species in the treatment group were lower than those in the control group, while the level of superoxide dismutase was higher than that in the control group (P < 0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant (P>0.05). Conclusion Edaravone dexborneol combined with argatroban significantly improves the clinical efficacy of AIS, effectively promotes the recovery of neurological function, improves the quality of daily life of patients, inhibits the expression of inflammatory factors, and reduces the level of serum free radicals.
- Edaravone dexborneol,
- Argatroban,
- Acute ischemic stroke,
- Neurological function,
- Inflammatory factors,
- Free radicals

FullText(HTML)

References(25)

References

[1]	GBD 2019 STROKE COLLABORATORS. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol, 2021, 20(10): 795-820. doi: 10.1016/S1474-4422(21)00252-0
[2]	中国医师协会神经内科医师分会脑血管病学组. 急性脑梗死缺血半暗带临床评估和治疗中国专家共识[J]. 中国神经精神疾病杂志, 2021, 47(6): 324-335. Stroke Group, Society of Neurology, Chinese Medical Doctor Association. Chinese expert consensus on clinical evaluation and treatment of ischemic penumbra in acute cerebral infarction[J]. Chinese Journal of Nervous and Mental Diseases, 2021, 47(6): 324-335.
[3]	POWERS W J, RABINSTEIN A A, ACKERSON T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2019, 50(12): e344-e418.
[4]	王虹, 王柳清, 张万里, 等. 静脉溶栓时间与急性轻型脑梗死及短暂性脑缺血发作患者早期认知功能的关系[J]. 中华全科医学, 2023, 21(1): 45-49. doi: 10.16766/j.cnki.issn.1674-4152.002808 WANG H, WANG L Q, ZHANG W L, et al. Relationship between time of intravenous thrombolysis and early cognitive function in patients with acute mild ischemic stroke and transient ischemic attack[J]. Chinese Journal of General Practice, 2023, 21(1): 45-49. doi: 10.16766/j.cnki.issn.1674-4152.002808
[5]	胡寅钦, 程记伟, 孙梦, 等. 阿加曲班治疗急性缺血性卒中疗效及安全性的系统评价及Meta分析[J]. 重庆医科大学学报, 2022, 47(7): 811-820. HU Y Q, CHENG J W, SUN M, et al. The efficacy and safety of argatroban in the treatment of acute ischemic stroke: a systematic review and meta-analysis[J]. Journal of Chongqing Medical University, 2022, 47(7): 811-820.
[6]	XU J, WANG A X, MENG X, et al. Edaravone Dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase Ⅲ, randomized, double-blind, comparative trial[J]. Stroke, 2021, 52(3): 772-780. doi: 10.1161/STROKEAHA.120.031197
[7]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志, 2024, 57(6): 523-559. Chinese society of neurology, Chinese stroke society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chinese Journal of Neurology, 2024, 57(6): 523-559.
[8]	吴正欢, 史俊, 周梦奇, 等. 依达拉奉右莰醇注射用浓溶液联合己酮可可碱治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2023, 38(3): 591-595. WU Z H, SHI J, ZHOU M Q, et al. Clinical study of Edaravone and Dexborneol Concentrated Solution for injection combined with pentoxifylline in treatment of acute cerebral infarction[J]. Drugs and Clinic, 2023, 38(3): 591-595.
[9]	李和侠, 刘惠娟, 尹伟, 等. 阿加曲班治疗急性期脑梗死52例临床疗效分析[J]. 中华全科医学, 2019, 17(7): 1112-1114, 1170. doi: 10.16766/j.cnki.issn.1674-4152.000876 LI H X, LIU H J, YIN W, et al. Clinical analysis of therapeutic effect of argatroban for acute cerebral infarction: a report of 52 cases[J]. Chinese Journal of General Practice, 2019, 17(7): 1112-1114, 1170. doi: 10.16766/j.cnki.issn.1674-4152.000876
[10]	COMER A R, TEMPLETON E, GLIDDEN M, et al. National Institutes of Health sroke scale (NIHSS) scoring inconsistencies between neurologists and emergency room nurses[J]. Front Neurol, 2023, 13: 1093392. DOI: 10.3389/fneur.2022.1093392.
[11]	SAVER J L, CHAISINANUNKUL N, CAMPBELL B C V, et al. Standardized nomenclature for modified rankin scale global disability outcomes: consensus recommendations from stroke therapy academic industry roundtable XI[J]. Stroke, 2021, 52(9): 3054-3062. doi: 10.1161/STROKEAHA.121.034480
[12]	FU M, FAN Y N, YAN S M, et al. Barthel index, SPAN-100, and NIHSS studies on the predictive value of prognosis in patients with thrombolysis[J]. Neurologist, 2024, 29(3): 158-162. doi: 10.1097/NRL.0000000000000554
[13]	吴健隆, 张潇, 江文. 缺血性脑卒中神经保护药物的临床研究进展[J]. 中国实用神经疾病杂志, 2023, 26(10): 1311-1316. WU J L, ZHANG X, JIANG W. Clinical research progress of neuroprotective drugs for ischemic stroke[J]. Chinese Journal of Practical Nervous Diseases, 2023, 26(10): 1311-1316.
[14]	CHENG Y R, LIU C N, LI S S, et al. Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis[J]. Front Neurol, 2024, 15: 1364895. DOI: 10.3389/fneur.2024.1364895.
[15]	ZHANG X T, ZHONG W S, XUE R, et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial[J]. JAMA Neurol, 2024, 81(2): 118-125. doi: 10.1001/jamaneurol.2023.5093
[16]	齐英斌, 许卓, 周艳, 等. 依达拉奉右莰醇对老年缺血性脑卒中患者脑细胞的保护作用[J]. 中国老年学杂志, 2024, 44(8): 2035-2037. QI Y B, XU Z, ZHOU Y, et al. Protective effect of edaravone and dexborneol on brain cells in elderly patients with ischemic stroke[J]. Chinese Journal of Gerontology, 2024, 44(8): 2035-2037.
[17]	郭慧, 秦鼎, 焦鸿云, 等. 依达拉奉右莰醇注射用浓溶液联合阿加曲班治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2023, 38(4): 834-839. GUO H, QIN D, JIAO H Y, et al. Clinical study of edaravone and dexborneol concentrated solution for injection combined with agatroban in treatment of acute cerebral infarction[J]. Drugs and Clinic, 2023, 38(4): 834-839.
[18]	ENDRES M, MORO M A, NOLTE C H, et al. Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke[J]. Circ Res, 2022, 130(8): 1167-1186. doi: 10.1161/CIRCRESAHA.121.319994
[19]	YALCINKAYA M, FOTAKIS P, LIU W L, et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion[J]. Cardiovasc Res, 2023, 119(4): 969-981. doi: 10.1093/cvr/cvac189
[20]	江娜, 许元, 冯林玉, 等. 中性粒细胞在缺血性脑卒中的作用研究进展[J]. 神经损伤与功能重建, 2023, 18(11): 651-655, 666. JIANG N, XU Y, FENG L Y, et al. Role of neutrophils in ischemic stroke[J]. Neural Injury and Functional Reconstruction, 2023, 18(11): 651-655, 666.
[21]	WANG D X, WANG Y T, SHI J F, et al. Edaravone Dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration[J]. Int Immunopharmacol, 2024, 130: 111700. DOI: 10.1016/j.intimp.2024.111700.
[22]	ZIETZ A, GOREY S, KELLY P J, et al. Targeting inflammation to reduce recurrent stroke[J]. Int J Stroke, 2024, 19(4): 379-387. doi: 10.1177/17474930231207777
[23]	BRIONES-VALDIVIESO C, BRIONES F, ORELLANA-URZŪA S, et al. Novel multi-antioxidant approach for ischemic stroke therapy targeting the role of oxidative stress[J]. Biomedicines, 2024, 12(3): 501. DOI: 10.3390/biomedicines12030501.
[24]	孙春梅, 唐玲, 庹玉平. 依达拉奉介导氧自由基清除促进脑卒中大鼠血脑屏障修复[J]. 徐州医科大学学报, 2022, 42(8): 583-587. SUN C M, TANG L, TUO Y P. Edaravone-mediated oxygen radical scavenging promotes blood-brain barrier repair in rats with stroke[J]. Journal of Xuzhou Medical University, 2022, 42(8): 583-587.
[25]	LI Y, REN M H, WANG J J, et al. Progress in borneol intervention for ischemic stroke: a systematic review[J]. Front Pharmacol, 2021, 12: 606682. DOI: 10.3389/fphar.2021.606682.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (21) PDF downloads(0)

Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke

doi: 10.16766/j.cnki.issn.1674-4152.004085

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical study of edaravone dexborneol combined with argatroban in the treatment of acute ischemic stroke

doi: 10.16766/j.cnki.issn.1674-4152.004085

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content